drugset / Trial / NCT07614321

Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

NCT07614321

Phase 4 Recruiting 60 enrolled Atlantic Health System
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS. Participants will: Take silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests

Timeline

Start
2026-04
Primary completion
2028-03
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Silodosin Unknown 8 mg Oral

Indications